Simvastatin, 20 mg 20

Hypolipidemic agent obtained synthetically from the fermentation product of Aspergillus terreus, is an inactive lactone, it undergoes hydrolysis in the body to form a hydroxy acid derivative.

The active metabolite inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), the enzyme that catalyzes the initial reaction of mevalonate formation from HMG-CoA.

Since the conversion of HMG-CoA to mevalonate represents an early stage of cholesterol synthesis, the use of simvastatin does not cause accumulation of potentially toxic sterols in the body.

HMG-CoA is easily metabolized to acetyl-CoA, which is involved in many synthesis processes in the body.

Causes a decrease in plasma triglycerides (TG), low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and total cholesterol (in cases of heterozygous familial and

Indications

Active ingredient

Composition

1 tablet contains:

The active ingredient:

Simvastatin;

Auxiliary substances:

MCC;

Lactose monohydrate (milk sugar);

Pregelatinized starch (starch 1500);

Colloidal silicon dioxide (aerosil);

Ascorbic acid;

Butyl hydroxyanisole;

Stearic acid;

Magnesium stearate;

Polyvinyl alcohol;

Macrogol (polyethylene glycol);

Iron oxide black dye;

Talc;

Iron oxide dye yellow;

Iron oxide dye red;

Titanium dioxide.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

None of the known few cases of overdose (maximum dose taken 450 mg) have shown specific symptoms.

Treatment: induce vomiting, take activated charcoal. Symptomatic therapy. Liver and renal functions and serum CPK levels should be monitored.

In case of myopathy with rhabdomyolysis and acute renal failure (a rare but severe side effect) the drug should be stopped immediately and the patient should be given a diuretic and sodium bicarbonate (intravenous infusion). Hemodialysis is indicated if necessary.

Rhabdomyolysis may cause hyperkalemia, which may be managed by intravenous calcium chloride or calcium gluconate administration, glucose and insulin infusion, use of potassium ion exchangers or, in severe cases, with hemodialysis.

Pregnancy use

Simvastatin may have adverse effects on the fetus and is contraindicated in pregnant women. There have been several reports of abnormalities in newborns whose mothers have taken Simvastatin.

Women of reproductive age taking Simvastatin should avoid conception. The use of Simvastatin is not recommended in women of childbearing age who do not use contraceptives.

If pregnancy does occur during treatment, Simvastatin should be discontinued and the woman should be warned of the possible risk to the fetus.

There are no data on excretion of Simvastatin with maternal milk.

If Simvastatin must be prescribed while breastfeeding, it should be taken into account that many drugs are excreted with breast milk, and there is a risk of severe reactions, so breastfeeding while taking the drug is not recommended.

Similarities